IMTX News & Events

Reports Q1 revenue $7.61M, consensus $10.41M. "Immatics is entering a pivotal period as we continue to progress toward the pre-specified interim and final analyses from the Phase 3 SUPRAME trial of anzu-cel and actively prepare for commercialization in 2027," said Harpreet Singh, Chief Executive Officer and Co-Founder of Immatics. "At the same time, we expect multiple meaningful clinical readouts across our PRAME franchise in 2026 that continue to validate PRAME as an important target across multiple solid cancers, extending well beyond melanoma, and across two different therapeutic modalities. Immatics today is a company defined not only by compelling science, but by a diversified late- and mid-stage clinical portfolio, growing commercial readiness, and a clear strategy to translate innovation into meaningful patient impact."

Immatics announced that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using Immatics' PRAME T-cell receptor has been accepted for a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting 2026 in San Diego, California. The patient case will be presented on April 21, at 2:00 pm PDT, by the treating physician, the company stated. Cedrik Britten, M.D., Ph.D., Chief Medical Officer at Immatics, said, "Seeing such a profound response in a pediatric patient who had no treatment options left is both remarkable and deeply encouraging for everyone dedicated to making a meaningful impact on the lives of patients with cancer. It reinforces our belief in PRAME as a powerful target and highlights the potential of cell therapy for pediatric cancers, where tumors often show high PRAME expression. These results support continued evaluation of PRAME-directed cell therapies in pediatric cancers while exploring new therapeutic options for children facing such devastating diseases."